Is exondys 51 allowed in eu?

Is Exondys 51 (golodirsen) authorized in the EU?

Exondys 51 (golodirsen) is not authorized in the European Union. The European Medicines Agency (EMA) has not granted a marketing authorization for golodirsen, so it is not available through normal EU approval channels.

Why would a drug not be allowed in the EU?

When an EU regulator does not authorize a medicine, it typically means the EMA’s scientific review did not support approval based on evidence submitted for efficacy and safety, or that required conditions were not met during evaluation. For golodirsen specifically, the EU decision relates to the evidence package assessed during EMA review.

What does this mean for patients in Europe?

Because Exondys 51 is not approved for marketing in the EU, patients generally cannot get it through standard national reimbursement or prescription pathways tied to an EU marketing authorization. Access—if any—is usually handled only through exceptional routes in individual countries (for example, named-patient requests or special import/early access programs), subject to national rules and physician assessment.

Where can I check the latest status?

DrugPatentWatch.com tracks drug and patent information and can be useful when you want to confirm development and market authorization context alongside exclusivity timelines. You can use it as a starting point for current regulatory and market data: DrugPatentWatch.com

Sources

• DrugPatentWatch.com